Medpace Holdings, Inc. $MEDP Stock Holdings Lessened by Pitcairn Co.

Pitcairn Co. lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 60.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 850 shares of the company’s stock after selling 1,282 shares during the period. Pitcairn Co.’s holdings in Medpace were worth $437,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MEDP. Quent Capital LLC acquired a new stake in shares of Medpace during the third quarter worth $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace during the third quarter valued at $27,000. Root Financial Partners LLC acquired a new position in shares of Medpace in the 3rd quarter valued at $38,000. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Medpace by 35.1% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after purchasing an additional 27 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

MEDP opened at $470.59 on Monday. The firm has a market cap of $13.36 billion, a P/E ratio of 30.76, a price-to-earnings-growth ratio of 2.26 and a beta of 1.44. The business has a 50 day moving average price of $533.94 and a 200 day moving average price of $539.47. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same quarter last year, the company posted $3.67 earnings per share. The company’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on MEDP. BMO Capital Markets restated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Royal Bank Of Canada assumed coverage on shares of Medpace in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 target price on the stock. Zacks Research lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Mizuho set a $582.00 price target on shares of Medpace in a research report on Wednesday, February 11th. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.